Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Anhedonia - the reduced ability to experience or respond to pleasure - is an important symptom domain for many psychiatric disorders. It is particularly relevant to depression and other mood disorders and it is a diagnostic criterion of a major depressive episode. Developing safe and effective pharmacological interventions for anhedonia is a critical public health need. The current chapter will review the state of the field with respect to both the efficacy of currently available pharmacotherapies for anhedonia and the recent clinical research focusing on new brain targets, including the kappa-opioid receptor and the KCNQ2/3 receptors. The evidence for anti-anhedonic effects of ketamine and psychedelic agents will be reviewed, as well. © 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.


Matthew E Klein, Ariela Buxbaum Grice, Sahil Sheth, Megan Go, James W Murrough. Pharmacological Treatments for Anhedonia. Current topics in behavioral neurosciences. 2022;58:467-489

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 35507281

View Full Text